• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕博西尼(PD 0332991)与激酶的相互作用。理论和比较分子对接研究。

Palbociclib (PD 0332991) Interaction with Kinases. Theoretical and Comparative Molecular Docking Study.

机构信息

Departamento de Ciencias Químicas, Facultad de Estudios Superiores Cuautitlán Campo 1, Universidad Nacional Autónoma de México, Avenida 1o de Mayo s/n, Colonia Santa María las Torres, Cuautitlán Izcalli, Estado de México, 54740, México.

Centro de Física Aplicada y Tecnología Avanzada, Universidad Nacional Autónoma de México, Boulevard Juriquilla, Querétaro, 76230, México.

出版信息

Chem Biodivers. 2023 Mar;20(3):e202200554. doi: 10.1002/cbdv.202200554. Epub 2023 Feb 17.

DOI:10.1002/cbdv.202200554
PMID:36799136
Abstract

The optimized geometry of palbociclib, (PD 0332991) (8-cyclopentyl-6-ethanoyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one), electrostatic potential map, molecular orbitals were calculated using the density functional theory. The geometry was used in a molecular docking study of palbociclib-kinase complexes, results could be explained by the charge of the nitrogen and oxygen atoms within the palbociclib. Energy gap of HOMO-LUMO surfaces, could help to explain the reactivity of the ligand and the hydrogen bonding with three different kinases, two of CDK6 and one of CDK4 type. Docking results are similar and complementary with literature reports using molecular dynamics, were hydrogen bonding was obtained and analyzed. The promiscuity of three kinases with palbociclib was detected by the docking results, thus, palbociclib could be used in other types of cancer besides myeloid leukemia. Some similarities are found with CDK4/CDK6 kinases which allow us to determine that palbociclib could be used to control other resistant inhibitor types of cancer.

摘要

帕博西尼(PD 0332991)(8-环戊基-6-乙酰基-5-甲基-2-(5-(哌嗪-1-基)吡啶-2-基氨基)吡啶并[2,3-d]嘧啶-7(8H)-酮)的优化几何形状、静电势图、分子轨道使用密度泛函理论计算。在帕博西尼-激酶复合物的分子对接研究中使用了该几何形状,结果可以用帕博西尼中氮和氧原子的电荷来解释。HOMO-LUMO 表面的能隙可以帮助解释配体的反应性和与三种不同激酶的氢键相互作用,其中两种为 CDK6,一种为 CDK4 型。对接结果与使用分子动力学获得和分析氢键的文献报道相似且互补。对接结果表明,三种激酶与帕博西尼的混杂性,因此,帕博西尼除了髓性白血病外,还可用于其他类型的癌症。与 CDK4/CDK6 激酶有一些相似之处,这使我们能够确定帕博西尼可用于控制其他耐药抑制剂类型的癌症。

相似文献

1
Palbociclib (PD 0332991) Interaction with Kinases. Theoretical and Comparative Molecular Docking Study.帕博西尼(PD 0332991)与激酶的相互作用。理论和比较分子对接研究。
Chem Biodivers. 2023 Mar;20(3):e202200554. doi: 10.1002/cbdv.202200554. Epub 2023 Feb 17.
2
Selective degradation of CDK6 by a palbociclib based PROTAC.基于帕博西尼的 PROTAC 选择性降解 CDK6。
Bioorg Med Chem Lett. 2019 Jun 1;29(11):1375-1379. doi: 10.1016/j.bmcl.2019.03.035. Epub 2019 Mar 26.
3
Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.细胞周期蛋白依赖性激酶4和6抑制剂帕博西尼的靶点结合化学蛋白质组学评估与癌细胞反应相关。
Biochemistry. 2016 Sep 27;55(38):5434-41. doi: 10.1021/acs.biochem.6b00629. Epub 2016 Sep 13.
4
Synthesis and Biological Evaluation of Novel Tc-Labeled Palbociclib Derivatives Targeting Cyclin-Dependent Kinase 4/6 (CDK4/6) as Potential Cancer Imaging Agents.新型 Tc 标记的帕博西尼衍生物的合成与生物学评价,作为潜在的癌症成像剂,靶向细胞周期蛋白依赖性激酶 4/6(CDK4/6)。
Mol Pharm. 2019 Oct 7;16(10):4213-4222. doi: 10.1021/acs.molpharmaceut.9b00540. Epub 2019 Aug 26.
5
Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.CDK4/6 抑制剂帕博西尼对乳腺癌细胞的抗细胞生长和抗肿瘤干细胞活性作用。
Breast Cancer. 2020 May;27(3):415-425. doi: 10.1007/s12282-019-01035-5. Epub 2019 Dec 10.
6
p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer.p27kip1 的表达和磷酸化决定了 KRAS 突变型结直肠癌对 Palbociclib 的敏感性。
Cell Death Dis. 2021 Oct 15;12(10):951. doi: 10.1038/s41419-021-04241-2.
7
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.帕博西尼与 BRAF 和 MEK 抑制剂协同作用对初治黑色素瘤有效,但对 BRAF 抑制剂耐药后无效。
Int J Cancer. 2018 May 15;142(10):2139-2152. doi: 10.1002/ijc.31220. Epub 2018 Jan 3.
8
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.乳腺癌中环磷酰胺依赖性激酶 4/6 抑制剂相关毒性和药物相互作用的临床处理:实用注意事项和建议。
Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13.
9
Multispectral and molecular simulation of the interaction of human α1-acid glycoprotein with palbociclib.人血清白蛋白与帕博西尼相互作用的多光谱和分子模拟。
Biochim Biophys Acta Gen Subj. 2024 Nov;1868(11):130712. doi: 10.1016/j.bbagen.2024.130712. Epub 2024 Sep 21.
10
The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time.参与雌激素受体阳性乳腺癌细胞对帕博西尼耐药的机制是多样的,并随时间而变化。
J Cancer Res Clin Oncol. 2021 Nov;147(11):3211-3224. doi: 10.1007/s00432-021-03722-3. Epub 2021 Jul 9.

引用本文的文献

1
Hybrid nucleobase-heterocycle-2-oxindole scaffolds as innovative cell cycle modulators with potential anticancer activity.杂合核碱基-杂环-2-吲哚酮支架作为具有潜在抗癌活性的创新细胞周期调节剂。
RSC Adv. 2025 Aug 22;15(36):29753-29776. doi: 10.1039/d5ra04997k. eCollection 2025 Aug 18.